The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.
about
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune ComplexesPharmacogenetics of treatment response in psoriatic arthritisEffectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuationUveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-αClinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.Efficacy and safety of emerging immunotherapies in psoriasis.Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.Learning Health Systems as Facilitators of Precision Medicine.The use of biologics in pregnant patients with rheumatic disease.Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range.British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritisAdalimumab-Induced Cutaneous Lupus Erythematosus in a 16-Year-Old Girl with Juvenile Idiopathic Arthritis.Treatment with Biologicals in Rheumatoid Arthritis: An Overview.Characterization of adherence and persistence profile in a real-life population of patients treated with adalimumab.Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.Safety of biologics in psoriasis.Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis.Immunogenicity of biologics in inflammatory bowel disease.Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin.Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.Immunogenicity of TNF alpha inhibitors in rheumatology: many questions, enough answers?[Systemic treatments for psoriasis and psoriatic arthritis].Anti-TNF-alpha antibody attenuates subarachnoid hemorrhage-induced apoptosis in the hypothalamus by inhibiting the activation of Erk.Clearing up potential misconceptions about the treatment of rheumatoid arthritis and the use of methotrexate in combination therapy.Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases
P2860
Q26766424-076D485C-9884-4FB8-8B30-7FE779E3B1B4Q28081252-332B9444-6DF5-4C60-A86E-20578D81F6ADQ30940329-6C6D2BB8-5923-4D7F-ACD2-B5AB292FAA8DQ30995889-546F48BB-EA4E-45A3-AA0B-EF7923437CF3Q34669637-4B22242C-93C5-4C82-87B2-2AD0BADD8BB9Q35635172-B28E3684-0B67-4DAB-A92A-CDFF64A411BBQ36231590-08C33578-6EB8-4B49-801D-7C03106F029CQ36832755-359CD848-1B38-445C-8C71-F44AA97A6CEDQ37517101-F9089B21-EEF2-4CCF-AD03-F2F59CDC1835Q37599165-62D7040D-3B3B-4057-8CB3-97506AB49CCBQ38207759-DA07EE88-EF49-4998-950C-CC77B35FD18AQ38365042-208B4E30-E944-4EA2-975B-7EB0DF87D9DEQ38411334-BF4BFB18-DD77-4B20-A3C2-859C455CC0B6Q38473460-B9E0AF7C-2004-4D04-9C71-2A6156CEFADDQ38540353-531EE21F-D562-4211-B857-3CF0958A45BEQ38631012-F29BBAED-4915-4058-95E4-FB87D27440A8Q38648460-05DF1A44-23FE-4A6F-BF02-7D6774007DE3Q38828876-0B658298-73C9-48C4-9ECE-1E39351F8283Q39041482-7176E77C-7A4C-4CB6-A06B-CAEC8C203AFBQ39192359-C4C7399D-27B5-45AE-BB01-ACFA9341DEF9Q39371316-C3A8FEFE-40B1-42A6-9BDF-51739E75045DQ40206740-F4966AA5-D2F9-4B5C-8083-538034305C06Q40590985-D0DF4577-DC3E-4529-AE89-432660332D3EQ41359123-7372F658-1A58-4E78-BB1A-05152C6897BEQ42682318-46B763C0-9BFC-4C40-9A76-24E8082BA075Q46068495-F24A21A9-2482-4A1D-86DE-37135599E4DFQ47132835-62C1786C-3480-4A53-A519-D7A7BA620993Q47258336-1CE5DF4B-557D-486A-B7F7-59F094BD23A4Q47380976-4236610A-0A3C-45CA-8C70-419793D2585DQ48144965-04662BBB-1C6F-4101-94F7-BD89931614E7Q48641283-8C78464F-BADF-408C-A6A3-B9C96EB45393Q49404676-1CD2DBD4-D9F6-4BD9-BDCC-BD29C38B7276Q50066277-F58ADC4A-24BD-4CE2-B13F-E97DA54FCE2DQ50083992-6941C93C-411A-495D-B954-2F0FABD9CBA2Q51397182-4BF21FCD-8443-4BF8-B3A5-67C03FA34EF3Q52851716-AC5135EF-B775-4167-A3B9-CB2F9EBE1355Q54964419-48302920-02AA-4D92-89AC-BA768156A314Q55073318-597BEB43-4A5E-4E01-9035-652C844C66B2Q58750029-B3617A2C-5B5A-44F7-BE88-89BFB8157632
P2860
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The role of DMARDs in reducing ...... chronic inflammatory diseases.
@en
type
label
The role of DMARDs in reducing ...... chronic inflammatory diseases.
@en
prefLabel
The role of DMARDs in reducing ...... chronic inflammatory diseases.
@en
P2860
P50
P921
P356
P1433
P1476
The role of DMARDs in reducing ...... chronic inflammatory diseases
@en
P2093
Christopher E M Griffiths
P2860
P304
P356
10.1093/RHEUMATOLOGY/KET260
P577
2013-08-14T00:00:00Z